Vor Bio Appoints Seasoned Healthcare Institutional Investor, Han Choi, M.D., LL.M., as Chief Financial Officer
Vor Bio (Nasdaq: VOR), a clinical-stage cell and genome engineering company, has appointed Han Choi, M.D., LL.M., as its new Chief Financial Officer. Dr. Choi brings over 25 years of experience in investment management, business development, and corporate strategy within the pharmaceutical and biotechnology industry. He will report directly to the company's President and CEO, Dr. Robert Ang.
Dr. Choi's expertise includes structuring corporate partnerships, managing complex transactions, and capital markets strategy. Prior to joining Vor Bio, he was a Principal at Oracle Investment Management, Inc., a healthcare-focused hedge fund. He has also held positions at Pharmacia and Bristol-Myers Squibb Company. Dr. Choi received his M.D. from Mount Sinai School of Medicine and law degrees from Oxford University and Harvard Law School.
Vor Bio (Nasdaq: VOR), una compagnia di ingegneria cellulare e genomica in fase clinica, ha nominato Han Choi, M.D., LL.M., come nuovo Direttore Finanziario. Il Dr. Choi porta con sé oltre 25 anni di esperienza nella gestione degli investimenti, sviluppo commerciale e strategia aziendale nel settore farmaceutico e biotecnologico. Riporterà direttamente al Presidente e CEO dell'azienda, Dr. Robert Ang.
Le competenze del Dr. Choi includono la strutturazione di partenariati aziendali, la gestione di transazioni complesse e strategie per i mercati dei capitali. Prima di entrare in Vor Bio, è stato Principal presso Oracle Investment Management, Inc., un fondo hedge focalizzato sulla salute. Ha inoltre ricoperto ruoli presso Pharmacia e Bristol-Myers Squibb Company. Il Dr. Choi ha conseguito la sua laurea in medicina presso la Mount Sinai School of Medicine e le lauree in giurisprudenza presso l'Università di Oxford e la Harvard Law School.
Vor Bio (Nasdaq: VOR), una compañía de ingeniería celular y genética en etapa clínica, ha nombrado a Han Choi, M.D., LL.M., como su nuevo Director Financiero. El Dr. Choi cuenta con más de 25 años de experiencia en gestión de inversiones, desarrollo de negocios y estrategia corporativa dentro de la industria farmacéutica y biotecnológica. Informará directamente al Presidente y CEO de la empresa, Dr. Robert Ang.
La experiencia del Dr. Choi incluye la estructuración de asociaciones corporativas, la gestión de transacciones complejas y estrategias de mercados de capitales. Antes de unirse a Vor Bio, fue Principal en Oracle Investment Management, Inc., un fondo de cobertura enfocado en la salud. También ha ocupado puestos en Pharmacia y Bristol-Myers Squibb Company. El Dr. Choi obtuvo su M.D. en Mount Sinai School of Medicine y títulos en derecho de la Universidad de Oxford y Harvard Law School.
Vor Bio(Nasdaq: VOR), 임상 단계의 세포 및 유전자 공학 회사가 한 최, M.D., LL.M.을 새로운 최고 재무 책임자(CFO)로 임명했습니다. 최 박사는 제약 및 생명공학 산업에서의 투자 관리, 비즈니스 개발 및 기업 전략 분야에서 25년 이상의 경험을 가지고 있습니다. 그는 회사의 회장 겸 CEO인 Dr. Robert Ang에게 직접 보고할 것입니다.
최 박사의 전문 분야에는 기업 파트너십 구조화, 복잡한 거래 관리 및 자본 시장 전략이 포함됩니다. Vor Bio에 합류하기 전, 그는 Oracle Investment Management, Inc.의 프린서펄로 재직했으며, 이는 의료 중심의 헤지펀드입니다. 그는 또한 Pharmacia와 Bristol-Myers Squibb Company에서 직책을 맡았습니다. 최 박사는 Mount Sinai School of Medicine에서 M.D.를 취득했고, 옥스포드 대학교와 하버드 로스쿨에서 법학 학위를 받았습니다.
Vor Bio (Nasdaq: VOR), une entreprise d'ingénierie cellulaire et génomique en phase clinique, a nommé Han Choi, M.D., LL.M., en tant que nouveau Directeur Financier (CFO). Le Dr. Choi apporte plus de 25 ans d'expérience en gestion d'investissements, développement commercial et stratégie d'entreprise dans l'industrie pharmaceutique et biotechnologique. Il rendra compte directement au Président et CEO de l'entreprise, Dr. Robert Ang.
Les compétences du Dr. Choi incluent la structuration de partenariats d'entreprise, la gestion de transactions complexes et des stratégies pour les marchés des capitaux. Avant de rejoindre Vor Bio, il était Principal chez Oracle Investment Management, Inc., un fonds spéculatif axé sur la santé. Il a également occupé des postes chez Pharmacia et Bristol-Myers Squibb Company. Le Dr. Choi a obtenu son M.D. de la Mount Sinai School of Medicine et des diplômes en droit de l'Université d'Oxford et de la Harvard Law School.
Vor Bio (Nasdaq: VOR), ein Unternehmen für Zell- und Genomtechnik in der klinischen Phase, hat Han Choi, M.D., LL.M., als neuen Finanzvorstand (CFO) ernannt. Dr. Choi bringt über 25 Jahre Erfahrung im Management von Investitionen, der Geschäftsentwicklung und der Unternehmensstrategie in der Pharma- und Biotechnologiebranche mit. Er wird direkt an den Präsidenten und CEO des Unternehmens, Dr. Robert Ang, berichten.
Die Expertise von Dr. Choi umfasst die Strukturierung von Unternehmenspartnerschaften, das Management komplexer Transaktionen und Strategien für die Kapitalmärkte. Bevor er zu Vor Bio kam, war er Principal bei Oracle Investment Management, Inc., einem auf Gesundheitswesen fokussierten Hedgefonds. Außerdem hatte er Positionen bei Pharmacia und Bristol-Myers Squibb Company inne. Dr. Choi erhielt seinen M.D. von der Mount Sinai School of Medicine sowie juristische Abschlüsse von der Universität Oxford und der Harvard Law School.
- Appointment of experienced CFO with 25+ years in healthcare investment and strategic operations
- New CFO brings expertise in structuring corporate partnerships and managing complex transactions
- Addition of a licensed physician and lawyer to the executive team, potentially enhancing decision-making
- None.
CAMBRIDGE, Mass., Sept. 30, 2024 (GLOBE NEWSWIRE) -- Vor Bio (Nasdaq: VOR), a clinical-stage cell and genome engineering company, today announced the appointment of Han Choi, M.D., LL.M., as its new Chief Financial Officer, effective immediately. Dr. Choi will join the Vor Bio leadership team and will report directly to the company’s President and Chief Executive Officer, Dr. Robert Ang.
Dr. Choi brings to Vor Bio over twenty-five years of experience in public and private investment management, business development, and corporate strategy within the pharmaceutical and biotechnology industry. His deep expertise in structuring corporate partnerships and investments, managing complex transactions, and capital markets strategy will play a critical role as Vor Bio advances its clinical pipeline and continues to expand its leadership in the field of cell and genome engineering.
"We are thrilled to welcome Han to Vor Bio," said Dr. Robert Ang, President and Chief Executive Officer of Vor Bio. "His extensive experience in healthcare investment and strategic corporate operations, coupled with his strong financial acumen, will be invaluable as we continue to drive our mission of transforming the treatment outcomes for patients with AML and other blood cancers."
Prior to joining Vor Bio, Dr. Choi was a Principal at Oracle Investment Management, Inc., a hedge fund that specializes in healthcare investments. For over two decades at Oracle, he was responsible for sourcing, negotiating, and managing investments in the pharmaceutical and biotechnology sectors, and provided strategic advice to portfolio companies on clinical, corporate development, and capital market strategies. Prior to joining Oracle, Dr. Choi held positions of increasing responsibility in licensing and business development at Pharmacia Corporation and Bristol-Myers Squibb Company. He received his M.D. from the Mount Sinai School of Medicine and holds law degrees from Oxford University and Harvard Law School. Dr. Choi is a licensed physician in New York State and a member of the New York State Bar.
"I am excited to join Vor Bio and contribute to the company’s growth and success," said Dr. Choi. "Vor Bio’s novel approach to treating blood cancer has the potential to transform outcomes for patients with AML and I look forward to working with the team to achieve our strategic and financial goals so that we can make a meaningful impact on patients' lives."
About Vor Bio
Vor Bio is a clinical-stage cell and genome engineering company that aims to change the standard of care for patients with blood cancers by engineering hematopoietic stem cells to enable targeted therapies post-transplant. For more information, visit: www.vorbio.com.
Inducement Equity Award
In connection with his appointment as the Company’s Chief Financial Officer, the Compensation Committee of the Board of Directors granted stock options to purchase an aggregate of 400,000 shares of Vor Bio’s common stock to Dr. Choi. The foregoing stock options were granted as a material inducement to employment with Vor Bio in accordance with Nasdaq Listing Rule 5635(c)(4) and were granted under the Vor Biopharma Inc. 2023 Inducement Plan (the “Inducement Plan”).
The stock options have a ten-year term and an exercise price equal to the closing price of Vor Bio’s common stock on September 30, 2024. The options will vest over a four-year period, with
Forward-Looking Statements
This press release contains forward-looking statements within the meaning of the Private Securities Litigation Reform Act of 1995. The words “aim,” “anticipate,” “can,” “continue,” “could,” “design,” “enable,” “expect,” “initiate,” “intend,” “may,” “on-track,” “ongoing,” “plan,” “potential,” “should,” “target,” “update,” “will,” “would,” and similar expressions are intended to identify forward-looking statements, although not all forward-looking statements contain these identifying words. Forward-looking statements in this press release include Vor Bio’s statements regarding the potential of its product candidates to positively impact quality of life and alter the course of disease in the patients it seeks to treat and other statements that are not historical fact. Vor Bio may not actually achieve the plans, intentions, or expectations disclosed in these forward-looking statements, and you should not place undue reliance on these forward-looking statements. Actual results or events could differ materially from the plans, intentions and expectations disclosed in these forward-looking statements as a result of various factors, including: uncertainties inherent in the initiation and completion of preclinical studies and clinical trials and clinical development of Vor Bio’s product candidates; availability and timing of results from preclinical studies and clinical trials; whether interim results from a clinical trial will be predictive of the final results of the trial or the results of future trials; expectations for regulatory approvals to conduct trials or to market products; the success of Vor Bio’s in-house manufacturing capabilities and efforts; and availability of funding sufficient for its foreseeable and unforeseeable operating expenses and capital expenditure requirements. These and other risks are described in greater detail under the caption “Risk Factors” included in Vor Bio’s most recent annual or quarterly report and in other reports it has filed or may file with the Securities and Exchange Commission. Any forward-looking statements contained in this press release speak only as of the date hereof, and Vor Bio expressly disclaims any obligation to update any forward-looking statements, whether because of new information, future events or otherwise, except as may be required by law.
Contacts:
Media & Investors:
Sarah Spencer
+1 857-242-6076
sspencer@vorbio.com
FAQ
Who is the new CFO of Vor Bio (VOR)?
What is Han Choi's background before joining Vor Bio (VOR)?
What are Han Choi's qualifications for the CFO role at Vor Bio (VOR)?
How might Han Choi's appointment impact Vor Bio's (VOR) future strategies?
